Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From medac GmbH
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- Generic Drugs
- Other Names / Subsidiaries
- medac Gesellschaft für klinische Spezialpräparate mbH
- medac GmbH Sp. z o.o.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.